Immuneering Corp - Ordinary Shares Class A

+0.78 (+6.33%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)339.82M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$0.55 Million
Adjusted EPS-$0.42
See more estimates
10-Day MA$13.78
50-Day MA$20.36
200-Day MAN/A
See more pivots

Immuneering Corp - Ordinary Shares Class A Stock, NASDAQ:IMRX

245 Main Street, 2nd floor, Cambridge, Massachusetts 02142
United States of America
Phone: +1.617.500.8080
Number of Employees:


Immuneering Corp. engages in the development of new medicines which are unlikely to be found by traditional drug discovery methods. Its pipeline of drug candidates focuses on treating aspects of disease that have eluded conventional approaches, including cancer cachexia and metastasis. The company was founded by Robert J. Carpenter and Benjamin J. Zeskind in 2008 and is headquartered in Cambridge, MA.